Xcout Intel
Latigo Biotherapeutics competitors & alternatives
The 12 closest competitors and alternatives to Latigo Biotherapeutics among biotech companies — ranked by similarity to what Latigo Biotherapeutics actually does, not by market-cap band.
Subscribe to see Latigo Biotherapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Latigo Biotherapeutics
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Latigo Biotherapeutics at a glance
Latigo Biotherapeutics is a biotech company headquartered in Thousand Oak, United States. It is publicly listed (LTGO) with a market capitalisation of $1.2B. Xcout tracks 24 named people at Latigo Biotherapeutics, including Nima Farzan (CEO, President & Director).
Latigo Biotherapeutics leadership
- Nima FarzanCEO, President & Director
- Neha KrishnamohanChief Business Officer & CFO
- Tim LugoChief Financial Officer
- Neil Kumar SinglaChief Medical Officer
- Bryan MoyerSenior Vice President of Discovery
- Julia ChapmanSenior Vice President of Operations
18 more named people on record for Latigo Biotherapeutics, with roles, board committees and tenure — see the full roster →
Recent Latigo Biotherapeutics news
- IPOLatigo Biotherapeutics, Inc. Common Stock IPO on NASDAQ
- IPOIPO registration (S-1)
- IPOBiotech Sets IPO Terms Behind Non-Opioid Pain Pipeline
- IPOIPO registration (S-1)
7 corporate events on record, with sources — see the full timeline →
Top 12 Latigo Biotherapeutics competitors
Ranked by semantic similarity — how close each company is to Latigo Biotherapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences & Healthcare
Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, non-opioid products for pain management.
Biotechnology
Bexson Biomedical is a US-based biopharmaceutical company situated in Santa Barbara, California, focused on the research and development of non-opioid therapeutics and drug delivery systems.
Biotechnology
Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel non-opioid therapeutics for the treatment of chronic pain and painful conditions.
Biotechnology
Amalgent Therapeutics develops fixed-dose combination therapies that pair opioids with dopamine-modulating adjuvants to provide safe pain management. The company's lead program, AMGT-0220, is designed to reduce required opioid doses, mitigate tolerance development, and lower reward signaling to help patients recover without the risks of conventional opioid treatments.
Biotechnology
TigaTx is a Boston-based biotechnology company founded in 2018 that is developing a pipeline of therapies targeting various cancer types and infectious diseases.
Biotechnology
Soteria Biotherapeutics, Inc. is a biopharmaceutical company founded in 2018 and headquartered in San Francisco, California, specializing in biopharmaceutical advancements and drug pipelines.
Similar biotech company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Biotechnology
Daya CNS, LLC is a preclinical biopharmaceutical company that develops a proprietary non-opioid pyridoindole platform for the treatment of chronic pain, substance abuse disorders, and neuropsychiatric conditions. Its product pipeline includes small molecule medications such as DDD-028 for neuropathic and inflammatory pain, DDD-024 for addiction, and DDD-016 for neuropsychiatric disorders, serving patients with unmet medical needs in neurology and addiction medicine.
Biotechnology
SantoSolve is a Norwegian biotechnology company based in Oslo that develops targeted pain therapeutics and non-radioactive strontium-based topical analgesic pharmaceutical products. Founded in 2002, the company focuses on treatments for pain and inflammatory conditions.
Biotechnology
Allay Therapeutics, Inc. is a biotechnology company headquartered in San Jose, United States, that focuses on developing advanced pain management products.
Biotechnology
Laigo Bio is a biotechnology company that develops targeted protein degradation therapeutics using its proprietary SureTAC platform. The company utilizes bispecific antibodies to direct cell surface targets toward lysosomal degradation, primarily serving the oncology and immunology sectors.
Biotechnology
Theragene Pharmaceuticals, Inc. is a privately held biopharmaceutical company headquartered in Los Angeles, California, focusing on immunotherapy technologies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Latigo Biotherapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Latigo Biotherapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →